Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 28;10(4):408-416.
doi: 10.1097/APO.0000000000000355.

Emerging Therapies in Nonexudative Age-Related Macular Degeneration in 2020

Anindya Samanta  1 , Aamir A Aziz  2 , Mahima Jhingan  3 , Sumit Randhir Singh  3 , Arshad M Khanani  2   4 , Jay Chhablani  5
Affiliations
Free article
Review

Emerging Therapies in Nonexudative Age-Related Macular Degeneration in 2020

Anindya Samanta et al. Asia Pac J Ophthalmol (Phila). .
Free article

Abstract

Age-related macular degeneration (AMD) is one of the most common causes of severe vision loss in the developed world. Advanced forms of AMD are seen in primarily 2 types, exudative AMD involving the presence of choroidal neovascularization and nonexudative or dry AMD with geographic atrophy. For the latter, the combination of vitamins and minerals known as the Age-Related Eye Disease Study-2 formulation has been shown to decrease the rate of progression of nonexudative to exudative AMD, as no other treatments are currently approved for nonexudative AMD. This review will highlight upcoming treatments for nonexudative AMD. Six upcoming agents have shown results at least in the 2A phase. This includes intravitreal agents that are inhibitors of integrin (Risuteganib), intravitreal agents that disrupt the complement pathway (Zimura, APL-2), neuroprotective implants (Brimonidine DDS), a subcutaneous injectable (Elamipretide), and photobiomodulation (Valeda Light Delivery System).

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: A.K. is serving as a consultant in Adverum, Alcon, Allegro, Allergan, Bausch and Lomb, Chengdu Kanghong Biotechnology Co., Genentech, Gemini, Gyroscope, Inc., Eyepoint, Kodiak Sciences Inc., Novartis, Opthea, Oxurion, PolyPhotonix, Recens, Regenxbio, and Roche; a research support in Adverum, Allergan, Chengdu Kanghong Biotechnology Co., Gemini, Genentech, Inc., Roche, Novartis, Gyroscope, Kodiak Sciences Inc., Novartis, Opthea, Ophthotech, Oxurion, and Regenxbio; and is receiving lecture fees from Allergan, Genentech, Inc., and Novartis. J.C. is serving in Novartis; Allergan; and OD-OS. All the other authors declare no conflicts of interest.

References

    1. Elshatory Y, Feldman B, Tripathy K, et al. Age-related macular degeneration - EyeWiki. Aaoorg 2019; https://eyewiki.aao.org/Age-related_macular_degeneration
    1. Bressler NM, Bressler SB, Congdon NG, et al. Potential public health impact of age-related eye disease study results: AREDS report no. 11. Arch Ophthalmol 2003; https://doi.org/10.1001/archopht.121.11.1621 - DOI
    1. Coleman HR, Chan CC, Ferris FL, et al. Age-related macular degeneration. Lancet 2008; 372:P1835–P1845.
    1. Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1992; 99:933–943.
    1. Owen CG, Jarrar Z, Wormald R, et al. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol 2012; 96:752–756.

Substances

LinkOut - more resources